Innovative Bispecific Nanobody Targeting LRP5/6 for Cancer Therapy

VHH-P699 is a humanized bispecific nanobody designed to target both LDL receptor related protein 5 (LRP5) and LDL receptor related protein 6 (LRP6). Currently in the Biological Testing stage, VHH-P699 addresses critical pathways implicated in cancer by simultaneously engaging these two receptors. The nanobody's unique design enables high specificity for LRP5 and LRP6, presenting a targeted strategy with the potential to disrupt oncogenic signaling central to tumor progression. By leveraging the advantages of nanobody technology, VHH-P699 represents a novel approach in the development of therapeutics aimed at various forms of cancer involving these key molecular targets.

Licensing Opportunity

VHH-P699 is available for out-licensing and strategic collaborations. We welcome inquiries from partners interested in innovative nanobody-based cancer therapies targeting LRP5 and LRP6, and look forward to exploring opportunities for co-development and commercialization.

Development Phase

Modality

VHH-P699 employs a humanized bispecific single-domain antibody (nanobody) format, engineered to bind both LRP5 and LRP6 simultaneously. This modality is characterized by its single variable heavy chain domain structure, resulting in a molecule of small size and high stability. Such structural features confer superior tissue penetration and the potential for enhanced tumor accessibility, both critical for effective cancer therapies. Compared to conventional antibodies, nanobodies like VHH-P699 offer increased solubility and resilience to harsh conditions, supporting diverse administration routes and therapeutic contexts. The bispecific nature further allows concurrent blockade of two oncogenic targets, bolstering its potential efficacy in the cancer setting.

Target

LRP5 and LRP6 are members of the low-density lipoprotein receptor family and play vital roles as co-receptors in Wnt/β-catenin signaling, a pathway fundamental to cell proliferation, differentiation, and survival. LRP5 and LRP6 are predominantly expressed in embryonic tissues, the central nervous system, and many adult organs, including the liver and bone. Of note, aberrant activation of the Wnt signaling pathway via LRP5 and LRP6 is closely linked to the development and progression of multiple cancer types, making these molecules compelling targets for oncologic intervention. The dual targeting strategy of VHH-P699 against LRP5 and LRP6 presents strategic value by potentially disrupting redundant or compensatory mechanisms in tumor cells, increasing the probability of therapeutic response and offering differentiation from monospecific approaches.

Mechanism of Action

VHH-P699 functions by selectively binding to LRP5 and LRP6, thereby inhibiting their activity within Wnt/β-catenin signaling in cancer cells. By blocking ligand access or receptor activation, VHH-P699 is designed to suppress a cascade that supports tumor growth, survival, and metastatic potential. The nanobody format allows not only direct antagonism of LRP5 and LRP6 but also provides a flexible platform for further development as antibody-drug conjugates or other bispecific constructs, enabling tailored engagement of immune effector functions or cytotoxic payload delivery. The dual blockade is anticipated to counteract compensatory signaling, addressing resistance mechanisms associated with single-targeted therapies and expanding therapeutic avenues in oncology.

Cancer

Cancer remains a major global health challenge with high incidence and mortality rates. The disease encompasses a diverse group of malignancies characterized by uncontrolled cell growth and the potential for metastasis. Current standard treatments include surgery, chemotherapy, radiation therapy, and a growing number of targeted therapies and immunotherapies. Despite recent advances, many patients face limited long-term outcomes due to issues such as resistance, toxicity, and lack of selectivity with existing treatments. Unmet medical needs persist, especially for aggressive, relapsed, or refractory cancers. The development of precision therapeutics targeting molecular drivers like LRP5 and LRP6 responds to the urgent demand for more effective, safer, and personalised cancer treatments. VHH-P699 is uniquely positioned to address these needs by offering a novel, targeted approach that may overcome limitations of existing standards while fitting into the evolving landscape of cancer care.